Introduction Medications for opioid use disorder (MOUD) are evidence-based treatments, yet
can be controversial among some populations. This study provides a systematic review of …

Background Despite evidence that medications to treat opioid use disorder (OUD) are
effective, most people who could benefit from this treatment do not receive it. This rapid …

At least 2.3 million people in the US have an opioid use disorder, less than 40% of whom
receive evidence-based treatment. Buprenorphine used as part of medication-assisted …

PURPOSE Despite the efficacy of buprenorphine-naloxone for the treatment of opioid use
disorders, few physicians in Washington State use this clinical tool. To address the acute …

The US is confronted with a rise in opioid use disorder (OUD), opioid misuse, and opioid-
associated harms. Medication treatment for opioid use disorder (MOUD)—including …

Aim Our aim was to compare physician-reported barriers to sublingual buprenorphine (BUP)
and extended-release naltrexone (XR-NLT) prescribing in US office-based practices, and to …

Background Patients and clinicians have begun to recognize the advantages and
disadvantages of buprenorphine relative to methadone, but factors that influence choices …

Background: The dissemination and adoption of research into clinical practice in health care
settings is a complex and challenging process. Clinical champions have been increasingly …

Abstract The US Department of Veterans Affairs (VA), the largest health care system in the
US, has been confronted with the health care consequences of opioid disorder (OUD) …

Background The opioid epidemic is a major public health issue associated with significant
overdose deaths. Effective treatments exist, such as the medication buprenorphine, but are …